Metastatic Malignant Neoplasm in the Brain Clinical Trial
Official title:
Efficacy of Post-Surgical Stereotactic Radiosurgery for Metastatic Brain Disease: A Randomized Trial
This randomized phase III trial studies stereotactic radiosurgery to see how well it works compared to clinical observation after surgery in treating patients with brain metastases. Stereotactic radiosurgery, a type of radiation therapy, may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
PRIMARY OBJECTIVES: I. To evaluate benefit of post-surgical stereotactic radiosurgery (SRS) on the resection bed in providing 6 month local control (decreasing the risk of local tumor recurrence) when compared to surgical resection alone. SECONDARY OBJECTIVES: I. Overall survival, development of distant brain metastases and complications related to treatment. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients undergo stereotactic radiosurgery to the surgical cavity within 30 days of the craniotomy. ARM II: Patients undergo clinical observation after craniotomy. After completion of study treatment, patients are followed up at 5-8 weeks, every 6-9 weeks for 1 year, every 3-4 months for 1 year, and then every 6 months thereafter. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04062305 -
nTMS in Planning Stereotactic Radiosurgery in Patients With Brain Metastases in the Motor Cortex
|
N/A | |
| Recruiting |
NCT05388877 -
E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma
|
Phase 1 | |
| Completed |
NCT03071913 -
Blood Brain Barrier Differences in Patients With Brain Tumors Undergoing Surgery
|
||
| Active, not recruiting |
NCT02595905 -
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
|
Phase 2 | |
| Recruiting |
NCT03270059 -
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
|
Phase 2 | |
| Terminated |
NCT00096265 -
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
|
Phase 3 | |
| Completed |
NCT02858869 -
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
|
Phase 1 | |
| Active, not recruiting |
NCT04250545 -
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT05341349 -
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases
|
Phase 1 | |
| Active, not recruiting |
NCT04114981 -
Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease
|
Phase 3 | |
| Recruiting |
NCT03741673 -
Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
|
Phase 3 | |
| Completed |
NCT03680144 -
Utility of Perfusion MRI to Detect Radiation Necrosis in Patients With Brain Metastases
|
N/A | |
| Completed |
NCT02167204 -
18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors
|
N/A | |
| Recruiting |
NCT03750227 -
Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors
|
Phase 3 | |
| Terminated |
NCT00659126 -
Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors
|
Phase 2 | |
| Recruiting |
NCT03418961 -
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT02993146 -
Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
|
Phase 1 | |
| Not yet recruiting |
NCT06328686 -
Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases
|
Early Phase 1 | |
| Active, not recruiting |
NCT02589522 -
Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
|
Phase 1 | |
| Recruiting |
NCT04804644 -
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
|
Phase 3 |